---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-086079"
form_type: "8-K"
ticker: "SXTP"
cik: "0001946563"
company_name: "60 DEGREES PHARMACEUTICALS, INC."
filed_at: "2024-10-08T23:59:59+00:00"
generated_at: "2026-05-30T18:20:16.215646+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# 60 Degrees Pharmaceuticals launches 9-month promotional pilot for ARAKODA malaria drug

## Summary
- Nine-month pilot includes virtual sales reps and co-pay program to boost ARAKODA awareness and sales.
- ARAKODA is the only FDA-approved antimalarial covering all stages of malaria, with weekly dosing.
- Company plans expanded U.S. sales effort in 2025 based on pilot data.
- CEO Geoffrey Dow says pilot will inform how healthcare professionals view ARAKODA.

## SEC filing metadata
- accession: 0001213900-24-086079
- form_type: 8-K
- ticker: SXTP
- cik: 0001946563
- company_name: 60 DEGREES PHARMACEUTICALS, INC.
- filed_at: 2024-10-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1946563/000121390024086079/0001213900-24-086079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1946563/000121390024086079/ea0217026-8k_60degrees.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-086079
- JSON: https://secwatch.observer/filing/0001213900-24-086079.json
- Plain text: https://secwatch.observer/filing/0001213900-24-086079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.